Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eleven cases of histologically proven transitional cell carcinoma of the bladder or urethra of the dog were selected for evaluation and characterization of the varied radiographic appearances of the lungs. In the 8 dogs with metastases, those appearances included radiographically normal pulmonary parenchyma, a semidense, diffuse, lacelike haze referred to as interstitial opacity, nodular interstitial opacity, and consolidations. One affected dog had hilar lymphadenopathy. In the 3 dogs without pulmonary metastases, the radiographic appearance was either normal pulmonary parenchyma or increased unstructured interstitial opacity. Of all dogs in the study, 6 had a radiographic appearance of increased unstructured interstitial opacity. Four of those 6 had histologically proven metastases in the peribronchiolar lymphatics or alveolar capillaries. Dyspnea was not identified in any of the affected dogs. The radiographic appearance for 3 of the 8 dogs with pulmonary metastases was misinterpreted as opacity compatible with age. The radiographic appearance for 1 of the 3 dogs without pulmonary metastases was misinterpreted as highly suspect for metastases.
 ...
PMID:Radiographic appearance of pulmonary metastases from transitional cell carcinoma of the bladder and urethra of the dog. 646 38

Fifty-seven patients with transitional cell carcinoma of the bladder, categories pT2, pT3a and pT3b, were treated by transurethral resection of the tumour mass (54 cases) or partial cystectomy (3 cases) followed by 8 doses of methotrexate 2 g i.v. every 3 weeks with appropriate Leucovorin rescue. At completion of chemotherapy 6 months after TUR 33/57 patients were tumour-free; 5/57 had new superficial tumours; 13/57 had persistent tumour invading muscle, 3 showed tumour progression and 3 had died from treatment complications. One-year survival was 45/57 (82%); 2-year survival was 23/39. Although some patients developed metastases and others have grown new superficial tumours, of those surviving, the bladder was free of the original invasive tumour in 38/45 (84%) at 1 year and in 19/24 (79%) at 2 years. It is concluded that transurethral resection plus high dose methotrexate may offer an effective alternative to radiotherapy or cystectomy for a significant proportion of patients with invasive bladder cancer.
 ...
PMID:Treatment of invasive bladder cancer by local resection and high dose methotrexate. 653 87

A neoplasm of unknown origin in cervical and axillary lymph nodes was diagnosed as anemone cell tumor by ultrastructural examination. Three years after the initial diagnosis of anemone cell tumor, a high-grade transitional cell carcinoma of the bladder was discovered. The results of immunoperoxidase staining of the cervical lymph node, axillary lymph node, and bladder tumors for keratin, carcinoembryonic antigen, and human chorionic gonadotropin (HCG) strongly suggest that the anemone cell tumors in this case represent metastases of bladder carcinoma cells capable of producing HCG.
 ...
PMID:The probable origin of an anemone cell tumor: metastatic transitional cell carcinoma producing HCG. 653 94

Five patients between 72 and 82 years old received 5 to 6 treatments of 50 to 75 mg. per m.2 cisplatin by bilateral internal iliac artery infusion for unirradiated invasive transitional cell carcinoma of the bladder. Of the patients 3 also were diabetics and 1 had congestive heart failure. Treatment was tolerated extremely well, although most courses were associated with moderate to severe nausea and vomiting lasting several hours. Of 4 evaluable patients 3 achieved complete remission and 1 achieved a good partial remission. An additional 55-year-old woman with a large invasive bladder carcinoma fixed to surrounding structures was treated with 4 courses of 100 mg. per m.2 intra-arterial cisplatin. This patient had a marked decrease in tumor size, permitting surgical resection of all known residual tumor. A 49-year-old patient with large pelvic lymph node metastases from a squamous cell carcinoma of the bladder achieved only minimal decrease in tumor size after 3 courses of 100 mg. per m.2 intra-arterial cisplatin. We conclude that intra-arterial cisplatin can be highly effective for localized invasive bladder cancer even when relatively low doses are used. With proper care the regimen can be used safely and effectively in elderly patients with medical contraindications to an operation.
 ...
PMID:Intra-arterial cisplatin treatment of unresectable or medically inoperable invasive carcinoma of the bladder. 653 37

Transitional cell carcinoma of the bladder has remained to date basically a surgical disease with the addition of preoperative radiation therapy to increase survival. Chemotherapy for bladder cancer is administered either in an adjuvant setting or in patients with metastatic disease, most of whom have been treated already with cystectomy and/or radiation. We report a complete response at 54 months in a patient with clinical stage D2 and pathologic stage D1 carcinoma using cisplatin, doxorubicin and cyclophosphamide. The patient was treated with urinary diversion and chemotherapy alone, and no attempt was made to remove the primary lesion.
 ...
PMID:Case report: complete response of metastatic transitional cell carcinoma of the bladder with chemotherapy alone. 653 39

Forty-one evaluable patients with bidimensionally measurable metastases of transitional cell carcinoma of the bladder were treated with cisplatin 70 mg/m2 i.v. on day 1 and VM-26 100 mg/m2 i.v. on days 1 and 2, every 3 weeks. Response was evaluated after 2 treatment cycles. Complete response (CR) was achieved in 4 patients (10%) and partial response (PR) in 17 (41%). The median response duration was 6 months. In this group of previously untreated patients the combination of cisplatin and VM-26 did not appear to yield better response rates than would be expected from cisplatin alone.
 ...
PMID:Combination chemotherapy with cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder. 653 94

Of 99 patients who had carcinoma-in situ (TIS) at least once between 1970 and 1980, 84 were subjected to detailed analysis and pathologic review. They may be classified into four groups: (Group 1) 14 patients, who presented with invasive bladder carcinoma (TCC) associated with TIS; (Group 2) 15 patients who, subsequent to the diagnosis of TIS with or without another superficial TCC developed muscle invasion (12 patients) or metastases without muscle invasion (three patients); (Group 3) 29 patients who underwent cystectomy for superficial TCC (Ta or T1, or TIS alone). Twenty (69%) had extravesical superficial extension. Two patients developed metastases subsequent to undergoing cystectomy; and (Group 4) 26 patients with TIS proven at least once who have not developed muscle invasion, metastases nor have undergone cystectomy. Nineteen had previous non-TIS superficial TCC. All patients in Groups 2 and 4 were treated conservatively (TUR +/- intravesical chemotherapy) when the initial diagnosis of TIS was made. Twelve patients in Group 3 underwent cystectomy within a month of the diagnosis of TIS. When 38 patients found to have TIS in association with the first diagnosis of superficial transitional cell carcinoma of the bladder were compared with 32 patients who had TIS diagnosed subsequent to their initial diagnosis of transitional cell carcinoma, the former group fared significantly worse (P less than 0.01) in regard to muscle invasion, metastases, or clinical indications for cystectomy.
 ...
PMID:Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. 686 Oct 89

Thirty-seven patients with measurable deposits or primary lesions arising from transitional cell carcinoma of the bladder were treated with 1 mg/m2/week of vincristine. One complete response lasting 7 months was seen among the 23 patients with metastatic disease. Two partial responses were seen among the 14 patients with persistent primary tumor. Vincristine is not recommended for further evaluation as a single agent in transitional cell carcinoma of the bladder.
 ...
PMID:Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study. 686 Nov 63

We have reviewed 111 patients with papillary transitional cell carcinoma of the bladder, category Ta and T1, admitted between 1975 and 1980. Histological grade and the presence of multiple tumours at presentation were the most useful prognostic features in terms of recurrence and mortality from either locally invasive or metastatic disease.
 ...
PMID:Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. 715 Sep 29

A retrospective analysis of 27 patients seen at UCLA in whom transitional cell carcinoma of the bladder developed at age forty or younger was conducted. Forty-one per cent had tumors manifesting known characteristics of aggressive and lethal potential: high histologic grade, muscular invasion, severe epithelial atypia, and frequent multifocal recurrence. One of these patients had extensive pelvic node metastases. The time from the first symptom, usually hematuria, to endoscopic diagnosis exceeded six months in 8 patients. The results of segmental cystectomy were very poor, in the absence of narrowly defined criteria for selection of this mode of therapy. No evidence was found to suggest that transitional cell carcinoma of the bladder in patients forty years of age and under differs clinically or morphologically from that of older patients. Treatment should be determined by the stage of the tumor and other indices of potential lethality.
 ...
PMID:Transitional cell carcinoma of bladder in first four decades of life. 717 21


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>